Revlimid and Agranulocytosis - a phase IV clinical study of FDA data
We study 360,904 people who have side effects when taking Revlimid. Agranulocytosis is found, especially among people who are male, 60+ old, have been taking the drug for < 1 month, also take Dexamethasone and have Myelodysplastic syndrome.
The phase IV clinical study analyzes which people take Revlimid and have Agranulocytosis. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
360,904 people reported to have side effects when taking Revlimid.
Among them, 7,410 people (2.05%) have Agranulocytosis.
What is Revlimid?
Revlimid has active ingredients of lenalidomide. It is used in multiple myeloma. Currently, eHealthMe is studying from 361,207 Revlimid users.
What is Agranulocytosis?
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 3,241 drugs and 3,460 conditions by eHealthMe. Currently, we are studying 199,063 people who have Agranulocytosis.
Number of Revlimid and Agranulocytosis reports submitted per year:
Time on Revlimid when people have Agranulocytosis *:
Gender of people who have Agranulocytosis when taking Revlimid*:
Age of people who have Agranulocytosis when taking Revlimid *:
Common drugs people take besides Revlimid *:
Common side effects people have besides Agranulocytosis *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Revlimid and have Agranulocytosis?Check whether Agranulocytosis is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Revlimid side effects by duration, gender and age:
- Revlimid side effects (361,207 reports)
Agranulocytosis treatments and more:
- Agranulocytosis (199,063 reports)
Common drugs associated with Agranulocytosis:
- Clozapine: 18,582 reports
- Cyclophosphamide: 10,824 reports
- Prednisone: 8,307 reports
- Carboplatin: 7,990 reports
- Methotrexate: 7,814 reports
- Revlimid: 7,410 reports
- Fluorouracil: 7,379 reports
- Cisplatin: 6,621 reports
- Etoposide: 5,855 reports
- Dexamethasone: 5,854 reports
All the drugs that are associated with Agranulocytosis:
- Agranulocytosis (3,241 drugs)
Common conditions associated with Agranulocytosis:
- Multiple myeloma: 9,913 reports
- High blood pressure: 5,594 reports
- Breast cancer: 5,558 reports
- Schizophrenia: 5,496 reports
- Non-hodgkin's lymphoma: 3,585 reports
All the conditions that are associated with Agranulocytosis:
- Agranulocytosis (3,460 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Remeron and Emphysema - a second ago
- Metoprolol Tartrate and Centrum Silver drug interaction - 8 seconds ago
- Loratadine and Nightmares - 10 seconds ago
- Prednisone and Hepatic Lesion - 11 seconds ago
- Nabumetone and Peripheral Swelling - 12 seconds ago
- Diphenhydramine Hydrochloride and Injection Site Swelling - 25 seconds ago
- Aldara and Respiratory Acidosis - 26 seconds ago
- Vitamin B2 and Bumex drug interaction - 29 seconds ago
- Ephedrine and Chills - 31 seconds ago
- Actifed and Temazepam drug interaction - 33 seconds ago